T1	Participants 99 121	breast cancer patients
T2	Participants 890 980	fifty-eight breast cancer patients who received chemotherapy or radiotherapy were enrolled
T3	Participants 1692 1917	administration of RG-CMH to patients receiving chemotherapy/radiotherapy may have the capacity to delay, or ease, the reduction in levels of leucocytes and neutrophils that are experienced by patients during cancer treatment.
